{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/COYA",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Coya Therapeutics, Inc. (NASDAQ: COYA) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Coya Therapeutics, Inc., listed on NASDAQ under ticker COYA, with ISIN US22407B1089 and LEI not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. The issuer is listed, not halted.\n\n## The disclosure read\n\nThe record holds 43 filings across 23 filing days in the window 2025-11-08 to 2026-11-08. Of these, 11 are directors' dealings, 8 are corporate news, 8 are regulatory filings, 8 are results, 3 are AGM or EGM filings, 3 are prospectuses, and 2 are director changes. The median gap between filing days is 10.0 days, against a NASDAQ median of 6.0 days and a sector median of 6.0 days. Latency from the latest filing to the record date is 25 days, against a NASDAQ median of 5.0 days and a sector median of 4.0 days. The latest filing is corporate news dated 2026-10-14.\n\n## Auditor\n\nThe auditor of record is Weaver and Tidwell, L.L.P., located in New York, NY. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting, or name change lines. The domicile change is not on the record, since EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, since the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's own investor-relations page names 6 research houses: BTIG, Chardan, HC Wainwright & CO, Lakestreet, LUCID, and ROTH.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record seals issuer years 2021, 2022, 2023, 2024, 2025, and 2026. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.\n\n## Sources\n\n9 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001835022.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/COYA (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1835022/000119312526107281/coya-20251231.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://ir.coyatherapeutics.com/stock-info/analyst-coverage/default.aspx (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/COYA (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1835022/000119312526107281/coya-20251231.htm",
    "state": "sourced",
    "value": "Weaver and Tidwell, L.L.P."
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1835022/000119312526107281/coya-20251231.htm",
    "state": "sourced",
    "value": "410"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1835022/000119312526107281/coya-20251231.htm",
    "state": "sourced",
    "value": "New York, NY"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/COYA",
  "coverage": {
   "count": 6,
   "houses": [
    {
     "analyst": "Thomas Shrader, PhD, CFA",
     "house": "BTIG",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.coyatherapeutics.com/stock-info/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Keay Nakae, CFA",
     "house": "Chardan",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.coyatherapeutics.com/stock-info/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Raghuram Selvaraju, Ph.D",
     "house": "HC Wainwright & CO",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.coyatherapeutics.com/stock-info/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Chad Messer, Ph.D.",
     "house": "Lakestreet",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.coyatherapeutics.com/stock-info/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Elemer Piros, PhD",
     "house": "LUCID",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.coyatherapeutics.com/stock-info/analyst-coverage/default.aspx",
     "state": "sourced"
    },
    {
     "analyst": "Boobalan Pachaiyappan",
     "house": "ROTH",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.coyatherapeutics.com/stock-info/analyst-coverage/default.aspx",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://ir.coyatherapeutics.com/stock-info/analyst-coverage/default.aspx",
     "result": "read: 6 of 12 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 3,
    "corporate_news": 8,
    "director_change": 2,
    "directors_dealings": 11,
    "prospectus": 3,
    "regulatory_filing": 8,
    "results": 8
   },
   "cadence_median_gap_days": 10,
   "filing_days": 23,
   "filings": 43,
   "latency_days": 25,
   "latest": [
    {
     "category": "8-K",
     "date": "2026-10-14",
     "source": "https://www.sec.gov/Archives/edgar/data/1835022/000119312526421066/d172621d8k.htm",
     "title": "8-K — 8-K (items 8.01)",
     "type": "corporate_news"
    },
    {
     "category": "8-K",
     "date": "2026-10-05",
     "source": "https://www.sec.gov/Archives/edgar/data/1835022/000119312526413218/d95167d8k.htm",
     "title": "8-K — 8-K (items 8.01)",
     "type": "corporate_news"
    },
    {
     "category": "8-K",
     "date": "2026-09-15",
     "source": "https://www.sec.gov/Archives/edgar/data/1835022/000119312526391378/d896544d8k.htm",
     "title": "8-K — 8-K (items 8.01)",
     "type": "corporate_news"
    },
    {
     "category": "10-Q",
     "date": "2026-08-11",
     "source": "https://www.sec.gov/Archives/edgar/data/1835022/000119312526343481/coya-20260630.htm",
     "title": "10-Q — 10-Q",
     "type": "results"
    },
    {
     "category": "8-K",
     "date": "2026-08-11",
     "source": "https://www.sec.gov/Archives/edgar/data/1835022/000119312526343473/coya-20260811.htm",
     "title": "8-K — 8-K (items 2.02,9.01)",
     "type": "results"
    }
   ],
   "latest_filing_date": "2026-10-14",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/COYA",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-13",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US22407B1089"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001835022.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-DE",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001835022.json",
    "state": "sourced",
    "value": "Coya Therapeutics, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001835022.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001835022.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "COYA"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:bd89132b7af820bcd6bab49e27032591c7d68859f4886ab395040105701d997c",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/COYA",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:bd89132b7af820bcd6bab49e27032591c7d68859f4886ab395040105701d997c",
 "path": "/us/NASDAQ/COYA",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Coya Therapeutics, Inc., listed on NASDAQ under ticker COYA, with ISIN US22407B1089 and LEI not on the record (no GLEIF record with the exact legal name in jurisdiction US-DE). Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States, Delaware. The issuer is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 43 filings across 23 filing days in the window 2025-11-08 to 2026-11-08. Of these, 11 are directors' dealings, 8 are corporate news, 8 are regulatory filings, 8 are results, 3 are AGM or EGM filings, 3 are prospectuses, and 2 are director changes. The median gap between filing days is 10.0 days, against a NASDAQ median of 6.0 days and a sector median of 6.0 days. Latency from the latest filing to the record date is 25 days, against a NASDAQ median of 5.0 days and a sector median of 4.0 days. The latest filing is corporate news dated 2026-10-14.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Weaver and Tidwell, L.L.P., located in New York, NY. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting, or name change lines. The domicile change is not on the record, since EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, since the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's own investor-relations page names 6 research houses: BTIG, Chardan, HC Wainwright & CO, Lakestreet, LUCID, and ROTH.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record seals issuer years 2021, 2022, 2023, 2024, 2025, and 2026. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "9 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001835022.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/COYA"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1835022/000119312526107281/coya-20251231.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://ir.coyatherapeutics.com/stock-info/analyst-coverage/default.aspx"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/COYA"
  }
 ],
 "title": "Coya Therapeutics, Inc. (COYA) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}